PARP1 and neoplasm: A clinical trial in 2015 (NCT01682772) tested the efficacy of olaparib, a PARP inhibitor, in treating mCRPC and found that treatment with olaparib prolonged radiographic progression–free survival (rPFS) and reduced circulating tumor-cell counts.